An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8
weeks, initiated in inpatients with bipolar depression. The study will consist of 9 visits
and 1 safety visit.
Inpatients with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute
depressive phase (i.e. bipolar depression) and being on stable medication with at least one
mood stabilizer.